8-K: MariMed Inc. Reports Third Quarter 2024 Results with Revenue Growth and Updated Financial Targets

MariMed Inc. announced its third quarter 2024 financial results, highlighting year-over-year and sequential revenue growth, along with updated full-year financial targets.

Summary

• MariMed Inc. reported its financial results for the third quarter ended September 30, 2024, showing revenue of $40.6 million, up from $38.8 million in the same period last year.
• The company experienced a GAAP net loss of $1.0 million for the quarter, an improvement from a $4.3 million loss in the prior year.
• Non-GAAP net income was $0.5 million, compared to a $3.1 million loss in the third quarter of 2023.
• Non-GAAP adjusted EBITDA was $4.7 million, down from $6.1 million year-over-year.
• The company's wholesale business saw a year-over-year growth of at least 20%, while retail transactions also increased due to same-store sales and new dispensaries.
• MariMed has updated its full-year 2024 revenue growth target to 6%-8%, up from 5%-7%, but revised its non-GAAP adjusted EBITDA target to a decline of 18%-20%, compared to the previous target of 0%-2% growth.
• Capital expenditures for 2024 are now expected to be $11 million, up from the previous target of $10 million.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company shows revenue growth and positive cash flow, the downward revision of EBITDA guidance and the net loss temper the positive aspects. The company's comments about M&A opportunities and a strong balance sheet are positive, but the overall tone is cautious due to the revised financial targets.

Positives

• MariMed achieved year-over-year and sequential revenue growth in the third quarter of 2024.
• The company experienced sequential improvement in EBITDA and net income.
• MariMed continues to generate positive operating cash flow.
• The wholesale business continues to show strong growth, outpacing the industry.
• Retail transactions increased year-over-year, indicating positive performance in the retail sector.
• The company has completed its heavy investment phase and significant pre-opening expenses.
• MariMed has a strong balance sheet, enabling it to pursue M&A opportunities.
• The company has commenced operations at new cultivation facilities in Maryland and Illinois, and manufacturing in Missouri.

Negatives

• The company experienced a GAAP net loss of $1.0 million for the third quarter of 2024.
• Non-GAAP adjusted EBITDA decreased to $4.7 million from $6.1 million in the same quarter of the previous year.
• The company has revised its full-year 2024 non-GAAP adjusted EBITDA target to a decline of 18%-20%.
• Capital expenditures for 2024 are now expected to be $11 million, up from the previous target of $10 million.
• Delays in securing regulatory approvals for new assets have led to higher-than-anticipated pre-opening costs and a longer ramp-up period.

Risks

• The company faces risks related to securing regulatory approvals for new assets, which can impact financial performance.
• Changes in demand for the company's services and products could affect revenue.
• Changes in laws and their enforcement could impact the business.
• The company is subject to risks related to the economic environment.
• The company's ability to recruit and retain key personnel could impact operations.
• Disruptions from the integration efforts of acquired companies could affect performance.

Future Outlook

MariMed expects 2025 to be another year of strong financial results, driven by margin improvements at recently opened locations and organic catalysts. The company also plans to capitalize on M&A opportunities due to its strong balance sheet.

Management Comments

• We reported year-over-year and sequential revenue growth, sequential EBITDA and Net Income improvement, and we continue to generate positive operating cash flow, said Jon Levine, Chief Executive Officer.
• Our wholesale business continues to outpace the industry with another quarter of at least 20% year-over-year growth.
• With 2024 nearly behind us, we continue to see margin improvements at our recently opened locations. This sets up 2025 as another year of strong financial results, said Mario Pinho, Chief Financial Officer.
• We have several organic catalysts to drive continued momentum for the foreseeable future.
• Additionally, we maintain one of the strongest balance sheets in the industry, enabling us to capitalize on attractive M&A opportunities in a market with depressed valuations.

Industry Context

MariMed operates in the multi-state cannabis market, which is experiencing growth but also faces regulatory and economic pressures. The company's focus on both wholesale and retail channels, along with its expansion into new states, aligns with industry trends. The company's comments about depressed valuations in the market suggest that the industry is currently experiencing a period of consolidation and M&A activity.

Comparison to Industry Standards

• MariMed's wholesale business growth of at least 20% year-over-year is a strong performance compared to many other cannabis operators, some of which are experiencing slower growth or even declines in wholesale revenue.
• The company's retail transaction growth, driven by same-store sales and new dispensaries, is in line with the industry trend of expanding retail presence to capture market share.
• While the company's GAAP net loss improved, it is still a loss, which is not uncommon in the cannabis industry, where many companies are still in the growth phase and investing heavily in expansion.
• The revised full-year 2024 non-GAAP adjusted EBITDA target of a decline of 18%-20% is a significant downward revision, which may be concerning to investors and is worse than many of its peers.
• Companies like Curaleaf, Trulieve, and Green Thumb Industries are often used as benchmarks in the cannabis industry, and MariMed's performance will likely be compared to these larger multi-state operators.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the revised EBITDA guidance and the net loss.
• Employees may be impacted by the company's expansion and operational changes.
• Customers will benefit from the increased availability of MariMed's products through new dispensaries and expanded cultivation.
• Suppliers may see increased demand for their products as MariMed expands its operations.
• Creditors may be impacted by the company's financial performance and capital expenditures.

Next Steps

• MariMed will host a conference call on November 7, 2024, to discuss the results.
• The company plans to continue expanding its operations and capitalize on M&A opportunities.
• MariMed expects the first harvest from its new cultivation facility in Mt. Vernon, Illinois, to be on shelves in the first quarter of 2025.
• The company plans to begin wholesale distribution of its branded products throughout Missouri by the end of November 2024.

Key Dates

Keywords

cannabis, MariMed, financial results, revenue, EBITDA, wholesale, retail, dispensary, cultivation, manufacturing, M&A, financial guidance